BeOne Medicines vs Teva Pharmaceutical Industries
ONC and TEVA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ONC and TEVA compare
BeOne Medicines is the larger company, worth 11 times as much as Teva Pharmaceutical Industries ($547B against $48.3B).
On earnings, Teva Pharmaceutical Industries is cheaper: it trades at 69.1× trailing earnings, against 861× for BeOne Medicines.
BeOne Medicines grew revenue faster over the last twelve months (34.3% versus −15.2% for Teva Pharmaceutical Industries).
BeOne Medicines keeps more of each dollar of sales as profit, with a net margin of 10.7% compared with 5.0% at Teva Pharmaceutical Industries.
BeOne Medicines scores higher on the StockData Score (12 against 7 for Teva Pharmaceutical Industries), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ONC | TEVA |
|---|---|---|
| Size and price | ||
| Market cap | $547B | $48.3B |
| Share price | $370.33 | $41.47 |
| Change, 1 year | 17.6% | 110% |
| Change, 5 years | 1.5% | 354% |
| Beta (5Y) | 1.07 | 0.99 |
| Employees | 12K | 34K |
| StockData Score | ||
| Total score | 12 (better) | 7 |
| Valuation score | 0 | 0 |
| Growth score | 3 (better) | 2 |
| Performance score | 4 | 4 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 861× | 69.1× (better) |
| P/S | 89.3× | 3.4× (better) |
| P/B | 106× | 6.2× (better) |
| EV/EBITDA | 504× | 19.0× (better) |
| P/FCF | 412× | 35.8× (better) |
| FCF yield | 0.24% | 2.8% (better) |
| Fair value | $15.35 | $18.65 |
| Margin of safety | −2313% | −122% (better) |
| Growth | ||
| Revenue growth (TTM) | 34.3% (better) | −15.2% |
| Revenue growth, 5Y average | 76.8% (better) | 0.71% |
| Profitability | ||
| Gross margin | 88.9% (better) | 64.4% |
| Operating margin | 15.1% (better) | 11.4% |
| Net margin | 10.7% (better) | 5.0% |
| FCF margin | 21.7% (better) | 9.6% |
| Return on equity | 14.7% (better) | 9.7% |
| Return on invested capital | 43.7% (better) | 23.0% |
| Financial health | ||
| Debt / equity | 0.22 (better) | 0.58 |
| Net debt / EBITDA | −3.67 | 0.33 (better) |
| Interest coverage | 8.7× | – |
| Current ratio | 3.40 (better) | 0.88 |
| Altman Z-score | 82.54 (better) | 0.84 |
| Piotroski F-score | 7 | 8 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 2.4% | – |
| Held by insiders | 13.9% | 0.43% |
| Insider net buying, 12 months | −$369M | −$113M (better) |
| Short interest, % of float | – | 2.6% |
Go deeper
- ONC stock overview
- ONC income statement
- ONC valuation and score
- TEVA stock overview
- TEVA income statement
- TEVA valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.